A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer

Wanling Xie, Sarah Drouin, Mari Nakabayashi, Mark Pomerantz, Gwo Shu Mary Lee, Philip W. Kantoff, Nima Sharifi

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Silencing SOD2 expression upregulates androgen receptor (AR) signaling and expression of SOD2 is downregulated in CRPC, compared with untreated tumors. The decreased SOD2 activity could lead to AR gain-of-function and the development of castration-resistance. METHODS: We genotyped SOD2-rs4880 in a cohort of 753 prostate cancer patients receiving androgen deprivation therapy (ADT) between 1996 and 2010. The rs4880 encodes Ala16Val in SOD2 and the Val variant has been demonstrated to be functionally less efficient than the Ala variant. We assessed the impact of SOD2-rs4880 variants on the time to progression (TTP) and overall survival (OS) on ADT using multivariable Cox regression. RESULTS: Four hundred thirty-two out of 753 (57%) had metastases at the time of ADT initiation. Overall, median TTP on ADT was 18.4 (95%CI: 15.8, 20.9) months and median overall survival (OS) from ADT initiation was 6.3 (95%CI: 5.8, 6.8) years. In unadjusted and adjusted analyses, there was no association between SOD-rs4880 and TTP or OS on ADT (P > 0.05). Results were similarly negative among patients with and without metastatic disease at ADT initiation. CONCLUSIONS: Our result suggests that a functional genetic variant in SOD2 does not determine the efficacy of ADT for prostate cancer. It is possible that the drastic downregulation of SOD2 in advanced prostate cancer cells may have overridden any influence of the genetic variation of SOD2. This study suggests the need for careful consideration about timing if the application of SOD2 mimetics for prostate cancer therapy is considered. Prostate 76:1338–1341, 2016.

Original languageEnglish (US)
Pages (from-to)1338-1341
Number of pages4
JournalProstate
Volume76
Issue number14
DOIs
StatePublished - Oct 1 2016

Fingerprint

Androgens
Prostatic Neoplasms
Therapeutics
Androgen Receptors
Survival
Down-Regulation
Castration
Prostate
Up-Regulation
Neoplasm Metastasis
Neoplasms

Keywords

  • MnSOD2
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Xie, W., Drouin, S., Nakabayashi, M., Pomerantz, M., Lee, G. S. M., Kantoff, P. W., & Sharifi, N. (2016). A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer. Prostate, 76(14), 1338-1341. https://doi.org/10.1002/pros.23220

A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer. / Xie, Wanling; Drouin, Sarah; Nakabayashi, Mari; Pomerantz, Mark; Lee, Gwo Shu Mary; Kantoff, Philip W.; Sharifi, Nima.

In: Prostate, Vol. 76, No. 14, 01.10.2016, p. 1338-1341.

Research output: Contribution to journalArticle

Xie, W, Drouin, S, Nakabayashi, M, Pomerantz, M, Lee, GSM, Kantoff, PW & Sharifi, N 2016, 'A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer', Prostate, vol. 76, no. 14, pp. 1338-1341. https://doi.org/10.1002/pros.23220
Xie, Wanling ; Drouin, Sarah ; Nakabayashi, Mari ; Pomerantz, Mark ; Lee, Gwo Shu Mary ; Kantoff, Philip W. ; Sharifi, Nima. / A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer. In: Prostate. 2016 ; Vol. 76, No. 14. pp. 1338-1341.
@article{eb8b56f9e0944d9f91f0914fe0eba82a,
title = "A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer",
abstract = "BACKGROUND: Silencing SOD2 expression upregulates androgen receptor (AR) signaling and expression of SOD2 is downregulated in CRPC, compared with untreated tumors. The decreased SOD2 activity could lead to AR gain-of-function and the development of castration-resistance. METHODS: We genotyped SOD2-rs4880 in a cohort of 753 prostate cancer patients receiving androgen deprivation therapy (ADT) between 1996 and 2010. The rs4880 encodes Ala16Val in SOD2 and the Val variant has been demonstrated to be functionally less efficient than the Ala variant. We assessed the impact of SOD2-rs4880 variants on the time to progression (TTP) and overall survival (OS) on ADT using multivariable Cox regression. RESULTS: Four hundred thirty-two out of 753 (57{\%}) had metastases at the time of ADT initiation. Overall, median TTP on ADT was 18.4 (95{\%}CI: 15.8, 20.9) months and median overall survival (OS) from ADT initiation was 6.3 (95{\%}CI: 5.8, 6.8) years. In unadjusted and adjusted analyses, there was no association between SOD-rs4880 and TTP or OS on ADT (P > 0.05). Results were similarly negative among patients with and without metastatic disease at ADT initiation. CONCLUSIONS: Our result suggests that a functional genetic variant in SOD2 does not determine the efficacy of ADT for prostate cancer. It is possible that the drastic downregulation of SOD2 in advanced prostate cancer cells may have overridden any influence of the genetic variation of SOD2. This study suggests the need for careful consideration about timing if the application of SOD2 mimetics for prostate cancer therapy is considered. Prostate 76:1338–1341, 2016.",
keywords = "MnSOD2, prostate cancer",
author = "Wanling Xie and Sarah Drouin and Mari Nakabayashi and Mark Pomerantz and Lee, {Gwo Shu Mary} and Kantoff, {Philip W.} and Nima Sharifi",
year = "2016",
month = "10",
day = "1",
doi = "10.1002/pros.23220",
language = "English (US)",
volume = "76",
pages = "1338--1341",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "14",

}

TY - JOUR

T1 - A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer

AU - Xie, Wanling

AU - Drouin, Sarah

AU - Nakabayashi, Mari

AU - Pomerantz, Mark

AU - Lee, Gwo Shu Mary

AU - Kantoff, Philip W.

AU - Sharifi, Nima

PY - 2016/10/1

Y1 - 2016/10/1

N2 - BACKGROUND: Silencing SOD2 expression upregulates androgen receptor (AR) signaling and expression of SOD2 is downregulated in CRPC, compared with untreated tumors. The decreased SOD2 activity could lead to AR gain-of-function and the development of castration-resistance. METHODS: We genotyped SOD2-rs4880 in a cohort of 753 prostate cancer patients receiving androgen deprivation therapy (ADT) between 1996 and 2010. The rs4880 encodes Ala16Val in SOD2 and the Val variant has been demonstrated to be functionally less efficient than the Ala variant. We assessed the impact of SOD2-rs4880 variants on the time to progression (TTP) and overall survival (OS) on ADT using multivariable Cox regression. RESULTS: Four hundred thirty-two out of 753 (57%) had metastases at the time of ADT initiation. Overall, median TTP on ADT was 18.4 (95%CI: 15.8, 20.9) months and median overall survival (OS) from ADT initiation was 6.3 (95%CI: 5.8, 6.8) years. In unadjusted and adjusted analyses, there was no association between SOD-rs4880 and TTP or OS on ADT (P > 0.05). Results were similarly negative among patients with and without metastatic disease at ADT initiation. CONCLUSIONS: Our result suggests that a functional genetic variant in SOD2 does not determine the efficacy of ADT for prostate cancer. It is possible that the drastic downregulation of SOD2 in advanced prostate cancer cells may have overridden any influence of the genetic variation of SOD2. This study suggests the need for careful consideration about timing if the application of SOD2 mimetics for prostate cancer therapy is considered. Prostate 76:1338–1341, 2016.

AB - BACKGROUND: Silencing SOD2 expression upregulates androgen receptor (AR) signaling and expression of SOD2 is downregulated in CRPC, compared with untreated tumors. The decreased SOD2 activity could lead to AR gain-of-function and the development of castration-resistance. METHODS: We genotyped SOD2-rs4880 in a cohort of 753 prostate cancer patients receiving androgen deprivation therapy (ADT) between 1996 and 2010. The rs4880 encodes Ala16Val in SOD2 and the Val variant has been demonstrated to be functionally less efficient than the Ala variant. We assessed the impact of SOD2-rs4880 variants on the time to progression (TTP) and overall survival (OS) on ADT using multivariable Cox regression. RESULTS: Four hundred thirty-two out of 753 (57%) had metastases at the time of ADT initiation. Overall, median TTP on ADT was 18.4 (95%CI: 15.8, 20.9) months and median overall survival (OS) from ADT initiation was 6.3 (95%CI: 5.8, 6.8) years. In unadjusted and adjusted analyses, there was no association between SOD-rs4880 and TTP or OS on ADT (P > 0.05). Results were similarly negative among patients with and without metastatic disease at ADT initiation. CONCLUSIONS: Our result suggests that a functional genetic variant in SOD2 does not determine the efficacy of ADT for prostate cancer. It is possible that the drastic downregulation of SOD2 in advanced prostate cancer cells may have overridden any influence of the genetic variation of SOD2. This study suggests the need for careful consideration about timing if the application of SOD2 mimetics for prostate cancer therapy is considered. Prostate 76:1338–1341, 2016.

KW - MnSOD2

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84982104896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982104896&partnerID=8YFLogxK

U2 - 10.1002/pros.23220

DO - 10.1002/pros.23220

M3 - Article

C2 - 27325180

AN - SCOPUS:84982104896

VL - 76

SP - 1338

EP - 1341

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 14

ER -